Collegium Pharmaceutical Inc (NASDAQ:COLL) has received an average recommendation of “Buy” from the ten brokerages that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $31.80.
Several brokerages have recently issued reports on COLL. TheStreet raised shares of Collegium Pharmaceutical from a “d+” rating to a “c” rating in a research note on Wednesday, March 7th. BidaskClub raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Thursday, February 15th. Piper Jaffray Companies set a $33.00 price objective on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a research note on Tuesday, January 23rd. HC Wainwright lifted their target price on shares of Collegium Pharmaceutical from $21.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, March 8th. Finally, William Blair reissued an “outperform” rating on shares of Collegium Pharmaceutical in a research report on Thursday, March 8th.
Collegium Pharmaceutical (NASDAQ:COLL) opened at $27.59 on Wednesday. Collegium Pharmaceutical has a 52 week low of $7.37 and a 52 week high of $29.90.
In other news, Chairman Michael Thomas Heffernan sold 20,000 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, January 23rd. The shares were sold at an average price of $25.01, for a total value of $500,200.00. Following the transaction, the chairman now directly owns 535,395 shares of the company’s stock, valued at $13,390,228.95. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Alison B. Fleming sold 6,928 shares of Collegium Pharmaceutical stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $19.07, for a total transaction of $132,116.96. Following the completion of the transaction, the insider now directly owns 32,651 shares in the company, valued at $622,654.57. The disclosure for this sale can be found here. Over the last three months, insiders sold 46,928 shares of company stock worth $1,082,317. 25.76% of the stock is currently owned by insiders.
Several institutional investors have recently added to or reduced their stakes in COLL. Voya Investment Management LLC purchased a new position in shares of Collegium Pharmaceutical in the second quarter worth approximately $125,000. Benjamin F. Edwards & Company Inc. boosted its holdings in shares of Collegium Pharmaceutical by 87.5% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 7,500 shares of the specialty pharmaceutical company’s stock worth $138,000 after purchasing an additional 3,500 shares during the period. Nationwide Fund Advisors boosted its holdings in shares of Collegium Pharmaceutical by 27.8% during the second quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock worth $161,000 after purchasing an additional 2,802 shares during the period. Acadian Asset Management LLC acquired a new stake in shares of Collegium Pharmaceutical during the fourth quarter worth approximately $176,000. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Collegium Pharmaceutical during the third quarter worth approximately $192,000. 87.60% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.americanbankingnews.com/2018/03/14/collegium-pharmaceutical-inc-coll-given-average-recommendation-of-buy-by-brokerages.html.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.